Sun Pharma Announces the Launch of ILUMYA for Treatment of Plaque Psoriasis.

Spread the love

ILUMYA is a humanized lgG1/k monoclonal antibody designed to selectively bind to the p19 subunit of IL-23 and inhibit its interaction with the IL-23 receptor, leading to inhibition of the release of pro-inflammatory cytokines and chemokines.

Junichi Nakamichi, Country Head, Sun Pharma Japan, said, “ILUMYA is Sun Pharma’s first innovative drug to be launched in the Japanese market. We are pleased to introduce a new, safe and effective treatment option for plaque psoriasis to doctors and patients in our country. This is an important milestone for Sun Pharma as we expand our product portfolio in Japan.” 


ILUMYA is contraindicated in patients with a previous serious hypersensitivity reaction to ILUMYA or to any other excipients.

ILUMYA may increase the risk of infection. Treatment with ILUMYA should not be initiated in patients with a clinically important active infection until the infection resolves or is adequately treated. Consider the risks and benefits of treatment prior to prescribing ILUMYA in patients with a chronic infection or a history of recurrent infection. Instruct patients receiving ILUMYA to seek medical help if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a clinically important or serious infection, or is not responding to standard therapy, closely monitor and discontinue ILUMYA until the infection resolves.

Evaluate patients for TB infection prior to initiating treatment with ILUMYA. Do not administer ILUMYA to patients with active TB infection. Initiate treatment of latent TB prior to administering ILUMYA. Consider anti-TB therapy prior to initiation of ILUMYA in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving ILUMYA should be monitored closely for signs and symptoms of active TB during and after ILUMYA treatment.

Most common (≥1%) adverse reactions associated with ILUMYA include upper respiratory infections, injection site reactions, and diarrhea. Adverse reactions that occurred at rates less than 1% but greater than 0.1% in the ILUMYA group and at a higher rate than in the placebo group included dizziness and pain in extremity.

About Psoriasis

Psoriasis is a chronic immune disease that appears on the skin, affecting approximately 125 million people worldwide.

The non-contagious disorder speeds the growth cycle of skin cells and results in thick scaly areas of skin. The most common form, affecting about 80 to 90 percent of people with psoriasis, is called plaque psoriasis.

It appears as red, raised areas of skin covered with flaky white scales which may be itchy and painful and can crack and bleed. Twenty percent of people with plaque psoriasis are considered moderate-to-severe, and many continue to struggle with the ongoing, persistent nature of this chronic disease.

Business Gujarat News

Leave a Reply

Your email address will not be published. Required fields are marked *

Next Post

UTI AMC IPO to open on September 29, price band fixed at Rs 552 - Rs 554

Thu Sep 24 , 2020
Spread the love The much-awaited initial public offer (IPO) of UTI Asset Management Company, one of the leading asset management companies (AMCs) in India, is […]
businessgujaratnews ©Copyright Theme: Default Mag by ThemeInWP

Quick Links